Navigation Links
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
Date:6/1/2009

s two through five of treatment), the study demonstrated a strong trend in favor of XERECEPT(R), though it did not reach statistical significance (p=0.1). Placebo patients tolerated a 50 percent reduction in dexamethasone dosing much better than anticipated over this time frame.

However, at weeks two, five, and eight, the XERECEPT(R) treatment group demonstrated an improved overall response rate based on the primary endpoint that was statistically significant at each time point. XERECEPT(R) demonstrated a highly statistically significant (p=0.001) improvement compared to placebo over the twelve weeks of study duration in reducing dexamethasone dose levels. Fifteen percent of patients on XERECEPT(R) were able to reach 0 mg of dexamethasone (p= 0.04) within the twelve week period.

Approximately 20 percent of the patients enrolled in NTI-0303 had metastatic brain tumors (secondary to primary tumors in the breast, lung or elsewhere). In this patient population, the primary and all secondary endpoints achieved a statistically significant advantage for XERECEPT(R) treated patients, exceeding the results observed in the overall patient cohort. This is an important finding given the 360,000 patients diagnosed annually with metastatic brain tumors in North America and Europe; moreover, patient prognosis is very poor and the treatment options are very limited.

In addition, the NTI-0303 trial showed that use of XERECEPT(R) leads to statistically significant reductions in steroid-related adverse events of myopathy (muscle weakness) and Cushingoid syndrome. Specifically, patients demonstrated a statistically significant increase in Ileopsoas muscle strength. These findings show a medically important clinical benefit for patients on XERECEPT(R).

NTI-0501

Results from NTI-0501, a Phase III open label extension study of patients rolling over from the 0302 and 0303 studies, demonstrated the
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
5. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... --  Physicians Interactive (PI) , leading provider of insight-driven ... pleased to announce that the company,s Chairman and CEO ... "Leading Growth for Good in Health and Wellness" executive ... 2016 , which takes place May 27–29 at the ... May 28, Tramuto will share how stakeholders across the ...
(Date:5/28/2015)... 2015 The global departmental PACS market ... , Europe , Asia ... departmental PACS market is expected to reach $3,807.4 million by ... Browse through the TOC of global departmental PACS ... segments, with help of various tables and figures. ...
(Date:5/28/2015)... , May 28, 2015 Cypher ... the Clinic for Special Children today announced a collaboration ... utilized for the diagnosis of rare genetic diseases among ... , the Clinic for Special Children (CSC) serves ... a relatively high incidence of genetic disease. ...
Breaking Medicine Technology:Physicians Interactive Chairman & CEO Donato Tramuto to Speak on Empowering Healthcare Consumers at Kellogg Innovation Network 2Physicians Interactive Chairman & CEO Donato Tramuto to Speak on Empowering Healthcare Consumers at Kellogg Innovation Network 3Departmental PACS Market is Expected to Reach $3,807.4 Billion by 2019, at a CAGR of 10.0% From 2014 to 2019 2Departmental PACS Market is Expected to Reach $3,807.4 Billion by 2019, at a CAGR of 10.0% From 2014 to 2019 3Cypher Genomics and Clinic for Special Children Collaborate on Rare Disease Study 2Cypher Genomics and Clinic for Special Children Collaborate on Rare Disease Study 3
... MOSCOW , May 24 The international forum "Drug Production ... in Moscow on June 9 and 10, 2010, at ... , Heads of ... in Moscow for a conference initiated by the Russian News & ...
... CHANGCHUN, China and LOS ANGELES , ... ("the Company"), one,of the leading health products distribution and retail sales companies in, ... 31, 2010 . , , , ... Revenues for the first quarter of 2010 were $10.68 million , ...
Cached Medicine Technology:Drug Production in Afghanistan: A Challenge for the International Community 2China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results 2China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results 3China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results 4China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results 5
(Date:5/28/2015)... 28, 2015 Boston Celtics Legend and ... both Genesis Foundation Board of Directors members, will be ... Fishing Tournament June 4-7. For the past 34 years, ... The Genesis Foundation for children by bringing together friends, ... The 34th John Havlicek Celebrity Fishing Tournament will be ...
(Date:5/28/2015)... The CEO and Founder of Alliance ... blog series which provides analysis on the benefits of ... Bruce Dalglish” profile on Blogger.com, this instructive new series ... experience. , “Throughout my business career, I’ve witnessed ... the overall success of businesses,” stated R. Bruce Dalglish, ...
(Date:5/28/2015)... Nidra Herbal Sleep Supplement features a 100% ... A non-addictive supplement, Nidra Herbal Sleep Supplement is more than ... leave users with a real sense of wellbeing the next ... which translates as the “Science or Knowledge of Life”, was ... is a holistic system of knowledge which combines contemplation, herbal ...
(Date:5/28/2015)... 28, 2015 Baptist Medical Center Jacksonville ... suffering from acute stroke or other neurological conditions. , ... of a few in the country and the first ... needs such as brain aneurysms. , “Baptist Health ... of patients who are impacted by stroke,” said Nicole ...
(Date:5/28/2015)... BC (PRWEB) May 28, 2015 ... Research ( http://www.idataresearch.com ), the shoulder reconstruction device ... orthopedic small bone & joint market in 2014. ... shoulder arthroplasty procedures in the U.S. due to ... improved device technology resulting in greater patient outcomes. ...
Breaking Medicine News(10 mins):Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:Ayurveda Herba Corp’s Revolutionary Herbal Sleep Supplement is Now Available from Amazon.com 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 3Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 3
... the women who suffer from osteoporosis from loss of bone ... a new device shows that it can help improve bone ... exercise is one of the principal recommendations for preventing and ... osteoporosis. However, exercise isn’t always possible, particularly for the frail., ...
... of Archives of Internal Medicine said that doctors might ... bio-terrorism that may be caused by smallpox, anthrax, botulism ... tested were unable to correctly diagnose diseases caused by ... test scores improved dramatically for the same physicians after ...
... You run the risk of getting diabetes if you ... surprising conclusion emerged when researchers at the Wake Forest ... and diabetes among participants in a major national study, ... of diabetes after five years among smokers and among ...
... a Herculean task to lose the excess weight that one ... flooding the market but the best way is that adopted ... down on the extra calories//. Obesity is a big problem ... - should be the mainstay of approach towards weight control. ...
... a walnut sized gland present below the urinary bladder in ... secretions that add volume to the semen//. Prostate cancer is ... cause of cancer death in American men. The incidence of ... respect to cancer prevention, an assessment of the risk factors ...
... is already a huge health problem in Asia that is ... 45 years (by 2050), one out of every two fractures ... the figures projected above, it would be sensible for men ... modification of their lifestyle. ,Osteoporosis, in which the ...
Cached Medicine News:Health News:Beauty Queens Urge On The Importance Of Maintaining Bone Integrity 2
...
... Storage in bottom of tray ... etc. Anodized aluminum. Durable and ... rust. Security locks ensure against ... bumper guards hold instruments in ...
Lance shaped gently curved tip. Flat serrated handle with polished finish....
For use with E0828 A needle tip and E0828 B gouge tip. Round knurled with threaded ended for tips. Most popular size or model....
Medicine Products: